New EU research projects approved:
This article was originally published in Clinica
Executive Summary
Funds totalling some E500 million ($500 million) are being allocated to 307 new research projects under the European Commission's quality of life and management of living resources programme. This is part of the European Union's fifth framework programme, and will cover subjects including genome research and cell factories. In the area of infectious disease, projects will aim to identify new anti-infective interventions and diagnostics and to develop the research base for epidemiological monitoring and rational public health practices. The cell factory programme, meanwhile, covers 26 health projects including neural regeneration, genes susceptible to melanoma and new biomarkers for skin damage.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.